Vanguard Global Advisers’s ADC Therapeutics ADCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$775 Buy
+635
New +$742 ﹤0.01% 3703
2026
Q2
– Sell
-31,593
Closed -$118K – 3641
2026
Q1
$118K Buy
+31,593
New +$125K ﹤0.01% 2659

Other funds holding ADCT

Vanguard Global Advisers's ADCT Position: Q3 2026 in Review

Vanguard Global Advisers opened a new position in ADC Therapeutics (ADCT) in Q3 2026: 635 shares worth $775. The stake represents ﹤0.01% of the portfolio and ranks #3703 among its holdings. This is a return to the name: Vanguard Global Advisers previously reported a position in ADCT as recently as Q1 2026.

Vanguard Global Advisers first reported a position in ADCT in Q1 2026 and has held it in 2 quarters since. The position peaked at $118K in Q1 2026. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.

  • Vanguard Global Advisers held 635 shares of ADC Therapeutics worth $775 as of Q3 2026.
  • ADC Therapeutics was a new Vanguard Global Advisers position in Q3 2026.
  • ADC Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3703 holding.
  • Vanguard Global Advisers first reported a position in ADC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's ADC Therapeutics position peaked at $118K in Q1 2026.
  • 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.